AIM
OMED

Acrospire Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Acrospire Investment Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,122
Closed -$101K – 2735
2016
Q4 		$101K Buy
+13,122
New +$121K 0.04% 921
2016
Q3 		– Sell
-907
Closed -$11K – 2369
2016
Q2 		$11K Buy
+907
New +$11K 0.01% 1745

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acrospire Investment Management's OMED Position: Q1 2017 in Review

Acrospire Investment Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2017, closing a stake of 13,122 shares — an estimated $101K sold.

Acrospire Investment Management first reported a position in OMED in Q2 2016 and held it in 2 quarters. The position peaked at $101K in Q4 2016. 85 funds tracked by Wall St. Rank hold OMED as of Q1 2017.

  • Acrospire Investment Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 13,122 OncoMed Pharmaceuticals, Inc. shares in Q1 2017, an estimated $101K.
  • Acrospire Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
  • Acrospire Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $101K in Q4 2016.
  • 85 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.